Clinical Development

Accro Bioscience Doses First Patient in AC-101 Phase IIb UC Trial

New York and Suzhou, China – September 21, 2026 -- Accro Bioscience Inc. has dosed its first patient in a Phase IIb trial testing AC-101, a selective RIPK2 inhibitor, in patients with moderate-to-severe ulcerative colitis (UC).

Trial spans roughly 50 clinical sites with three treatment arms

The multicenter, double-blind, placebo-controlled study is designed across approximately 50 clinical sites and includes two AC-101 dose cohorts plus a placebo control arm. The primary endpoint is clinical remission rate at Week 12, with exploratory endpoints covering histologic remission and long-term maintenance of clinical and histologic remission.

Sobi-Innate Pharma Deal Turns Effective, Triggers $75M Payment

Stockholm – September 20, 2026 -- Swedish Orphan Biovitrum AB (Sobi) has paid Innate Pharma SA USD 75 million as their strategic oncology partnership becomes legally effective, following the expiration of antitrust waiting periods and satisfaction of other closing conditions.

Partnership clears regulatory hurdles first announced September 20, 2026

The deal, initially disclosed on September 20, 2026, grants Sobi exclusive global commercialisation rights to lacutamab pending accelerated approval, with an option to assume full global development rights if Phase 3 results are positive.

Adora Life Science Names Dr. Clinton Morgan Chief Medical Officer

Franklin, Tennessee – September 20, 2026 -- Adora Life Science has appointed Dr. Clinton D. Morgan, MD, as its full-time Chief Medical Officer, effective September 20, 2026, the company announced.

Neurosurgeon exits clinical practice to lead human trials for veterinary-derived drug

Dr. Morgan previously served on Adora's Board of Directors and consulted part-time on the company's human therapeutic strategy. In his new role, he will direct Adora's human clinical development, regulatory strategy, and scientific research network, and will chair a newly assembled Scientific Advisory Board spanning glycobiology, osteoarthritis, and radiation injury experts.

ProBio, Kun Tuo Partner to Fast-Track Cell and Gene Therapy Trials in China

Hopewell, N.J. – September 19, 2026 -- ProBio, a global contract development and manufacturing organization (CDMO), has struck a strategic collaboration with Kun Tuo, an IQVIA-owned clinical research organization (CRO) in China, to integrate manufacturing and clinical trial execution for advanced therapies.

Partnership links CDMO manufacturing with CRO trial operations in China

The alliance combines ProBio's biologics and cell and gene therapy (CGT) development and manufacturing platform with Kun Tuo's clinical trial management network, targeting faster Investigator-Initiated Trials (IITs) for global biopharma sponsors entering the Chinese market. The integrated offering spans Chemistry, Manufacturing and Controls (CMC), non-clinical studies, and clinical operations under a single coordinated pathway.

Cardiol Therapeutics Files US$150M Shelf Prospectus, Expands OSC Disclosure

Toronto – September 17, 2026 -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) has filed a preliminary short form base shelf prospectus in Canada and a corresponding Form F-10 registration statement with the U.S. SEC, enabling the life sciences company to raise up to US$150 million over a 25-month period.

Shelf filing permits future issuance of shares, debt and warrants

The filings, made under the U.S./Canada Multijurisdictional Disclosure System, would allow Cardiol to offer Class A common shares, debt securities, warrants, subscription receipts, units, or combinations thereof, once a final receipt is issued and the Registration Statement becomes effective. No securities are being offered under this announcement, and the Company said there is no assurance an offering will occur.

AdJane Unveils Mucosal Booster Strategy for Respiratory Vaccines

Delft – September 16, 2026 -- AdJane Biosciences has published a white paper outlining a strategy to add mucosal immune stimulation to existing intramuscular respiratory vaccine regimens, using its clinically validated Nm-nOMV platform derived from Neisseria meningitidis outer membrane vesicles.

AdJane targets the mucosal gap left by intramuscular respiratory vaccines

Current intramuscular respiratory vaccines induce strong systemic immunity and protect against severe disease, but generate limited protection at the respiratory mucosa, the point where pathogens first enter the body. The company's white paper, titled 'Boosting mRNA: Mucosal Immunity and a Platform Beyond It,' argues that mucosal IgA responses can reduce transmission at the point of entry, a target public health bodies are pursuing alongside severe-disease prevention.

Cytonics Raises $4.8M, Hits 8,000 Investors for A2M Therapy

Jupiter, Florida – September 15, 2026 -- Cytonics Corporation has closed a financing campaign generating $4.8 million in gross proceeds, pushing its total capital raised to $47 million and expanding its investor base to approximately 8,000 shareholders.

Cytonics attracts 900 new investors as 35% of existing shareholders reinvest

The clinical-stage biotechnology company completed approximately 1,500 individual investments in the round, including roughly 900 first-time backers. Of the pre-raise shareholder base, 35% chose to invest again, according to the company. The raise brings cumulative funds secured through Regulation A and Regulation Crowdfunding offerings to $27 million.

ImmunoGenesis Adds Biopharma, Ex-USGA Chief to Board Ahead of 2027 Data

Houston – September 15, 2026 -- ImmunoGenesis has appointed Reza Mazhari, Ph.D., and Mike Davis to its Board of Directors as the clinical-stage biotech advances its lead immunotherapy candidate toward key data readouts in mid-2027.

ImmunoGenesis has initiated a Phase 1b trial for lead asset IMGS-001

IMGS-001, a cytotoxic checkpoint inhibitor targeting PD-L1 and PD-L2, is being studied for immune-excluded tumors, a category that accounts for more than half of all cancers. James Barlow, President and CEO of ImmunoGenesis, said the new board members will help shape pipeline, partnering and fundraising strategy for the company's next growth phase.